NDAORALFOR SOLUTIONPriority Review
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYGEVVI is an oral small-molecule combination product containing doxecitine and doxribtimine approved by the FDA on November 3, 2025. The mechanism of action and specific indications are not yet publicly detailed in available data. This formulation represents a novel oral solution approach from UCB Pharma.
Launch14.2 years to LOE
Early-stage launch product with potential for significant team expansion and market establishment over the next 24–36 months.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Doxecitine and Doxribtimine-Expanded Access
Thymine Kinase 2 Deficiency
Career Relevance
KYGEVVI is a newly launched product with significant career opportunity for professionals willing to build the brand from launch. Team growth across sales, marketing, medical affairs, and market access is likely as the product establishes market presence and indication footprint.
Brand Manager
Worked on KYGEVVI at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.